Oscient Pharmaceuticals Corporation (Nasdaq: GENE) has completed enrollment of an open-label, Phase II clinical trial of Ramoplanin, a novel, investigational oral antibiotic being developed for the treatment of Clostridium difficile-associated diarrhea (CDAD). Following completion of the last patient’s course of therapy and follow-up, the Company will conduct its analysis of the data and plans to release preliminary results. The Company anticipates submitting full results for publication or presentation at an upcoming medical conference. Based on the results observed to date in the trial, the Company expects to seek FDA authorization to commence a Phase III program for CDAD by the end of this year. Ramoplanin has Fast Track status from the FDA for this indication.
